SC 13G: Theravance Biopharma, Inc.

AI Summary

SC 13G filing by Theravance Biopharma, Inc..

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.00001 — NC. (Name of Issuer) ORDINARY SHARE $0.00001 PAR VALUE (Title of Class of Securiti

Filing Documents

• formsc13g.htm (SC 13G) — 89KB
• 0001493152-24-032810.txt ( ) — 90KB

From the Filing

SC 13G 1 formsc13g.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* THERAVANCE BIOPHARMA, INC. (Name of Issuer) ORDINARY SHARE $0.00001 PAR VALUE (Title of Class of Securities) G8807B106 (CUSIP Number) August 7, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. G8807B106 (1) Names of Reporting Persons Newtyn Management, LLC (2) Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) (3) SEC Use Only (4) Citizenship or Place of Organization New York Number of Shares Beneficially Owned by Each Reporting Person With: (5) Sole Voting Power: 4,100,000* (6) Shared Voting Power: 0 (7) Sole Dispositive Power: 4,100,000* (8) Shared Dispositive Power: 0 (9) Aggregate Amount Beneficially Owned by Each Reporting Person 4,100,000* (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions): (11) Percent of Class Represented by Amount in Row (9) 8.4%* (12) Type of Reporting Person (See Instructions) IA * See Item 4 for additional information. CUSIP No. G8807B106 (1) Names of Reporting Persons Newtyn TE Partners, LP (2) Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) (3) SEC Use Only (4) Citizenship or Place of Organization New York Number of Shares Beneficially Owned by Each Reporting Person With: (5) Sole Voting Power: 2,501,000* (6) Shared Voting Power: 0 (7) Sole Dispositive Power: 2,501,000* (8) Shared Dispositive Power: 0 (9) Aggregate Amount Beneficially Owned by Each Reporting Person 2,501,000* (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions): (11) Percent of Class Represented by Amount in Row (9) 5.1%* (12) Type of Reporting Person (See Instructions) PN * See Item 4 for additional information. Item 1(a). Name of Issuer. Theravance Biopharma, Inc. (the “Company”) Item 1(b). Address of Issuer’s Principal Executive Offices. C/O Theravance Biopharma US, Inc. 901 Gateway Boulevard South San Francisco, CA 94080 Item 2(a). Name of Person Filing. This report on Schedule 13G (this “Schedule 13G”) is being filed by (i) Newtyn Management, LLC, a New York limited liability company (“Newtyn Management”), and (ii) Newtyn TE Partners, LP, a Delaware limited partnership (“NTE”, and collectively with Newtyn Management, the “Reporting Persons”). Item 2(b). Address of Principal Business Office or, if None, Residence. The address for the Reporting Persons is 60 East 42 nd Street, 9 th Floor, New York, NY 10165. Item 2(c). Citizenship. Newtyn Management is organized under the laws of the State of New York. NTE is organized under the laws of the State of Delaware. Item 2(d). Title of Class of Securities. Ordinary share $0.00001 par value (the “Ordinary Shares”). Item 2(e). CUSIP No. G8807B106 Item 3. If This Statement Is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a: Not Applicable. Item 4. Ownership. As reported in the cover pages to this report, the ownership information with respect to Newtyn Management is as follows: (a) Amount Beneficially Owned: 4,100,000* (b) Percent of Class: 8.4%* (c) Number of Shares as to which the person has: (i) Sole power to vote or to direct the vote: 4,100,000* (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 4,100,000* (iv) Shared power to dispose or to direct the disposition of: 0 As reported in the cover pages to this report, the ownership information with respect to NTE is as follows: (a) Amount Beneficially Owned: 2,501,000* (b) Percent of Class: 5.1%* (c) Number of Shares as to which the person has: (i) Sole power to vote or to direct the vote: 2,501,000* (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 2,501,000* (iv) Shared power to dispose or

View Full Filing

View this SC 13G filing on SEC EDGAR